Since semaglutides patent expired in India in March 2026, generic prices have fallen by roughly 80%, with monthly costs now starting around 1,290 to 5,000 compared with 8,800 to 16,400 for older branded options
This compound is being explored primarily in the realm of metabolic and endocrine disorders, offering significant promise for improving treatment outcomes in conditions such as obesity, type 2 diabetes, and other related health issues
the difference is accessibility and costat $289/mo month-to-month, or from $249/mo on the 6-month plan with no insurance needed, no membership fees, and HSA/FSA eligibility
Semaglutide, in both injectable and oral formulations, appears to be a promising potential GLP-1R agonist in combination with conventional IOP-lowering agents to decrease the rate of glaucoma worsening
Dont leave them in a parked car, even for a short time
Native oxyntomodulin has significant glucoregulatory effects independent of weight loss in obese humans with and without type 2 diabetes